Diabetes drug cream shows promise for treating stubborn facial melasma
NCT ID NCT07485777
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a cream made from the diabetes drug metformin to the standard Kligman's regimen for treating melasma, a common skin condition causing dark patches on the face. About 82 women aged 35-55 will apply one of the two creams nightly for 8 weeks, along with sunscreen. Researchers will measure how much the dark patches fade and track side effects like redness or burning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
topical 30% metformin cream
What this could lead to
If it works, this could offer a new, gentler option for treating melasma with fewer side effects than standard therapy.
What could go wrong
This is a small, early-stage trial with only 82 participants. Metformin cream is not yet proven for melasma, and results may not apply to all skin types or ages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELASMA (FACIAL MELASMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fauji Foundation Hospital, Rawalpindi
Rawalpindi, Punjab Province, 44000, Pakistan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact